IL-17 mediates resistance to anti-VEGF therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24013745.
- Also identified by DOI 10.1038/nm.3333.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy.
Medical subject headings
- Angiogenesis Inhibitors
- Drug Resistance, Neoplasm
- Interleukin-17
- Neoplasms
- Neovascularization, Pathologic
- Th17 Cells
- Vascular Endothelial Growth Factor A